Featured content in this Issue:
Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure”
An “Unauthorized Disclosure”
“Canadian Reorganization”
“Cost Containment Initiatives”
Algernon Pharmaceuticals Makes DMT Stroke Research Program Its Lead Asset
atai Pivots to IV Formulation of Ibogaine
Seaport Therapeutics Launches with $100m Series A, Pipeline Includes ‘Prodrug of a Non-Hallucinogenic Neuroplastogen’
Otsuka and Click Score FDA Clearance for Rejoyn, First Prescription Digital Therapeutic for A Mental Health Condition.
Do Psilocybin Trial Participants Believe in the ‘Inner Healer’?
LSD Microdosing Improves Sleep, According to New Publication
“Petition for the FDA to Convene an Open Advisory Committee Meeting to Hear Concerns on MDMA-Assisted Therapy”
Companies, organisations and drug candidates mentioned in this Bulletin: Numinus Wellness; The Dales Report; Algernon Pharmaceuticals; AP-188; Seyltx; atai Life Sciences; IBX-210; DMX-1002; Seaport Therapeutics; Karuna; SPT-348; Otsuka; Click Therapeutics; Rejoyn; Lykos Therapeutics.
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
